Amprologix Selected for MassChallenge Switzerland & UK 2025 Accelerator - Amprologix Amprologix joins a global network of innovators We're proud to announce that Amprologix is one of the 103 finalists selected to participate in the MassChallenge Switzerland & UK Accelerator Programme ...

We're proud to announce that Amprologix is one of the 103 finalists selected to participate in the MassChallenge Switzerland & UK Accelerator Programme 2025, chosen from a pool of 1,527 high-potential startups worldwide.

Epidermicin NI01, a First-in-Class Peptide Antibiotic Candidate, Has Potent Efficacy in a Robust MRSA Wound Infection Model and Low Allergic Reaction Liabilities Over 10% of antibiotic prescriptions are for skin infections.1,2 New therapeutic approaches are required, and new modalities may be...

Epidermicin NI01, has been featured in EMJ Reviews following a presentation by CSO @matupton.bsky.social at @escmid.bsky.social Global 2025.

The data highlights efficacy in MRSA wound infections, and low risk of triggering allergic reactions - a promising step forward in the fight against AMR.

Studies shows new class of antibiotic is effective in tackling MRSA University of Plymouth news: The latest results of ongoing research by the University, and spinout company Amprologix, will be presented to leading...

@matupton.bsky.social, CSO, recently presented results from ongoing research at ESCMID Global 2025 - the Congress of the European Society of Clinical Microbiology and Infectious Diseases - in Vienna

www.plymouth.ac.uk/news/studies...

Genomic insights and phenotypic characterization of three multidrug resistant Cupriavidus strains from the cystic fibrosis lung AbstractAims. We aimed to investigate phenotypic and genomic traits of three Cupriavidus spp. isolates recovered from people with cystic fibrosis (PWCF). T

Genomics & phenotype of 3 Cupriavidus strains from cystic fibrosis lung - great team with PhD student Sean Kelly, @vickyb-micro.bsky.social @kmudz.bsky.social & clinical collaborators. High quality genomes, MDR to CF drugs, susceptible to pip/tazo & cefotax

academic.oup.com/jambio/artic...

Join us for 3 fun packed evenings at @bathbrewhouse to find out more about Our Bodies 👤🦵

Hear from researchers at the cutting edge of their fields, including @ella489.bsky.social and how she is making mini organs to study cancer! 🫀

🎟️ Tickets at pintofscience.co.uk/events/bath

#pint25

First publication with new group in Plymouth! @kmudz.bsky.social

Highlights included the moment I discovered that Cupriavidus spp are in fact meant to have 2 chromosomes, so my 2 chromosome + 2 plasmid mega assembly wasn't a complete fail 💪

doi.org/10.1093/jamb...

Bit of peer pressure never did anyone any harm 🙃

Yes @katburdon.bsky.social amazing!

www.the-microbiologist.com/features/a-c...

Cranberry juice won’t cut it: UTIs and the potential for repurposing drugs The winning essay in the Max Perutz science writing award 2021 was written by Vicky Bennett from the department of biology and biochemistry at Bath University

www.theguardian.com/science/2021...